BK virus (BKV) Infection Epidemiology Summary

• The BKV disease funnel is substantially larger at the viremia stage than at overt disease: In the US, approximately 25% of kidney transplant recipients develop BKV viremia, with a substantial proportion progressing to BKVAN. Using a 40% viremia-to-BKVAN progression rate, the epidemiologic funnel translates into a sizeable BKVAN population, underscoring why kidney transplantation represents the major reservoir of clinically relevant BKV disease.
• Although BKPyV is also clinically relevant in hematopoietic stem cell transplantation (HSCT), particularly in BKPyV-associated hemorrhagic cystitis, the most mature epidemiological and therapeutic evidence base remains concentrated in kidney transplantation.
• The viremia-to-BKVAN conversion is highly heterogeneous across the 7MM, reflecting differences in transplant populations, immunosuppressive regimens, screening frequency, viral-load thresholds, and diagnostic practices.
• The diagnosed prevalent cases of BKHC in the US are estimated at approximately 1,275 cases in 2025, representing the largest patient share across the 7MM, driven by the substantial volume of HSCT procedures and the resulting susceptibility to BK virus reactivation and hemorrhagic cystitis among transplant recipients.
• Among classification-specific BKVAN cases in kidney transplant recipients across EU4 and the UK, Class 2 represented the largest segment in 2025, with ~500 cases, followed by Class 1 at ~300 cases and Class 3 at ~95 cases. This distribution highlights Class 2 as the predominant histopathological grade within the diagnosed BKVAN population in the region.
• Across EU4 and the UK, autologous HSCT cases consistently outnumbered allogeneic HSCT cases, totaling ~15,500 versus ~12,500 in 2025, respectively. The higher volume of autologous HSCT reflects its broader utilization across hematologic malignancies, particularly multiple myeloma and lymphoma, whereas allogeneic HSCT is primarily used in selected patients with hematologic malignancies requiring donor-derived hematopoietic reconstitution.
• Reported BKPyV rates vary according to transplant population, immunosuppressive regimen, screening frequency, assay methodology, viral-load thresholds, and definitions of DNAemia versus nephropathy. The 2024 consensus guidelines specifically identify the need for improved international standards, better characterization of viral genotypes and variants, and optimization of screening intervals.
• In Japan, Grade 2 emerged as the leading severity level for HSCT-associated BKHC cases, accounting for ~405 cases in 2025, followed by Grade 3 at ~295 cases, while Grade 1 and Grade 4 remained equal at ~110 cases each.
• The diagnosed prevalent cases of BKV infection in the US are estimated at ~4,300 cases in 2025, representing the largest patient share among the 7MM. The higher diagnosed burden in the US may reflect its large transplant population, greater availability of routine BKV PCR-based surveillance, and broader recognition of BKV infection in immunocompromised patients, particularly kidney transplant recipients.

DelveInsight's "BK Virus Infection Epidemiology Forecast – 2036" report delivers an in-depth understanding of BK virus infection, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

BK Virus Infection Understanding

BK Virus Infection Overview and Diagnosis

BK virus (BKPyV), also known as a human polyomavirus, is a common virus that is typically acquired during childhood. Primary infection is usually asymptomatic or causes mild cold-like symptoms. After the initial infection, the virus remains latent for life in the kidneys and the epithelial lining of the ureters and urinary bladder. In healthy individuals, the immune system generally keeps the virus in a dormant state. However, when immune function is suppressed, BKV may reactivate and cause clinically significant infection. Reactivation occurs most commonly in kidney transplant recipients, who require long-term immunosuppressive therapy to prevent graft rejection. Active BKV infection can involve the kidneys, ureters, and bladder and may lead to renal injury.

The diagnosis of BKV infection relies on a combination of complementary laboratory and histopathological techniques, selected based on the clinical setting, the urgency of evaluation, and the available diagnostic infrastructure. Initial assessment typically includes quantitative polymerase chain reaction (PCR) testing for BK viral DNA in urine and plasma, with viruria serving as an early marker of viral reactivation and persistent viremia indicating an increased risk of BKVAN.

Further details are provided in the report...

BK virus infection Epidemiology

Key Findings from BK virus infection Epidemiological Analysis and Forecast

• The total number of BKVAN cases across the 7MM is expected to increase from approximately ~4000 cases in 2025, primarily reflecting the growing kidney transplant population, continued exposure to immunosuppressive therapy, and improved screening and surveillance for BKPyV DNAemia among kidney transplant recipients.
• Among BKVAN cases in US kidney transplant recipients, Class 2 represented the largest classification-specific segment, totaling ~1,650 cases in 2025.
• According to epidemiological analysis, BKVAN cases in kidney transplant recipients across EU4 and the UK totaled ~900 in 2025. Among these countries, France recorded the highest number of cases at ~350, followed by Italy at ~200 and the UK at ~170, while Germany reported the lowest count at ~35 cases.
• In Japan, allogeneic HSCT cases consistently outnumbered autologous HSCT cases, totaling ~3,750 versus ~2,100 in 2025.
• Among classification-specific BKVAN cases in kidney transplant recipients across EU4 and the UK, Class 2 represented the largest segment in 2025, with ~500 cases, followed by Class 1 at ~300 cases and Class 3 at ~95 cases. This distribution highlights Class 2 as the predominant histopathological grade within the diagnosed BKVAN population in the region.

Industry Experts and Physician Views for BK Virus Infection

To keep up with BK virus infection dynamic epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the BK virus infection epidemiology, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 20+ KOLs to gather insights at country level. Centers such as the University of Santo Tomas, Berlin Institute of Health at Charité, Paris-Est Créteil University, UCL Queen Square Institute of Neurology etc. were contacted.

Their opinion helps understand, validate, highlight and provide epidemiological context in BK virus infection.

Scope of the  BK virus infection Epidemiology Report

• The report covers a segment of an executive summary, a descriptive overview of BK virus infection, explaining their causes, signs and symptoms and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along diagnostic guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

BK virus infection Epidemiology Report Insights

• BK Virus Infection Patient Population Forecast
• Country-wise Epidemiology Distribution
• Total Cases of BK Viremia in Kidney Transplant Patients
• Total Cases of BKVAN
• Classification-specific Cases of BKVAN
• Type-specific HSCT Cases
• Total Cases of BKHC
• Grade-specific Cases of BKHC

BK virus infection Epidemiology Report Key Strengths

• Epidemiology based (Epi based) Bottom up Forecasting
• 11-year forecast
• Patient Burden Trends (by geography)
• The 7MM Coverage

Explore DelveInsight’s BK Virus Infection Market Forecast Report for comprehensive insights into market trends, epidemiology, emerging therapies, and forecasts through 2036.

FAQs

• BK virus infection Epidemiology Insights
• What is the forecast period covered in the report?
• How is epidemiological data collected and analyzed for forecasting purposes?
• Out of all EU4 countries and the UK, which country had the highest population of BK virus infection cases?
• What are the disease risks and burdens of BK virus infection?
• At what compound annual growth rate the population is expected to grow across the 7MM during the forecast period?
• What would be the forecasted patient population of BK virus infection at the 7MM level?

Reasons to Buy BK virus infection Epidemiology Report:

• The report will help in developing business strategies by understanding the latest epidemiology trends.
• Insights on patient burden/ prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand KOLs’ perspectives on the dynamic epidemiology trends.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions